-
Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Darb-Esfahani S, Loibl S, Müller BM, Roller M, Denkert C, Komor M, Schlüns K, Blohmer JU, Budczies J, Gerber B, et al.
Breast Cancer Res. 2009; 11(5):R69.
[Breast Cancer Res. 2009]
-
Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer.
Miles DW.
Breast Cancer Res. 2009; 11(4):208. Epub 2009 Aug 28.
[Breast Cancer Res. 2009]
-
Does vimentin help to delineate the so-called 'basal type breast cancer'?
Kusinska RU, Kordek R, Pluciennik E, Bednarek AK, Piekarski JH, Potemski P.
J Exp Clin Cancer Res. 2009 Aug 20; 28:118. Epub 2009 Aug 20.
[J Exp Clin Cancer Res. 2009]